Agomab is a biotechnology company developing therapies that maintains and restores organ function in diseases characterized by fibrosis.
AgomAb Therapeutics has raised $88.7M in total funding. The most recent round was Series D. The last funding was announced in October 2024.
AgomAb Therapeutics's investors include Cormorant Asset Management, Pfizer, Canaan Partners, Sanofi, Andera Partners.
AgomAb Therapeutics is headquartered in Antwerpen, Belgium.
Agomab is a biotechnology company developing therapies that maintains and restores organ function in diseases characterized by fibrosis.
AgomAb Therapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AgomAb Therapeutics — Funding & Investors." VCBacked, October 25, 2024, https://www.vcbacked.co/company/agomab-therapeutics. Accessed September 15, 2026.
VCBacked. (2024). AgomAb Therapeutics — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/agomab-therapeutics
{{cite web |title=AgomAb Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/agomab-therapeutics |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated